About the Study
CGRP Migraine treatment is a new type of treatment used to prevent and treat migraine pain. The first CGRP migraine medication was Aimovig that came to the market in May 2018. Aimovig and other CGRP medications (i.e. Emgality) are now available on the market to help prevent and treat migraines. It works by blocking a protein called CGRP, or calcitonin gene-related peptide, which may cause inflammation and pain in the nervous system of people who have migraine attacks. Post-marketing data suggests that certain CGRP drugs cause more constipation than others. This study compares the constipation rate of these two drugs.
The purpose of this study is to measure gastrointestinal transit time in adult patients with migraines before and after initiation of CGRP medication. This study will be open label and you will either be given galcanezumab (Emgality) or erenumab (Aimovig) . You will use a wireless motility capsule (WMC) technology that tracks and records the speed of your stomach emptying. This will be done before and after the medication is administered. The data will be compared between the two drugs to see which causes more constipation. All medications and devices used in this study are currently FDA approved and readily available on the market.
The study will last approximately 2 months with 5 visits to our office. Compensation for time and travel will be available, for those who qualify. Study related care is provided to participants at no cost. Health insurance is not required or needed.
- Between the ages of 18-55 years old
- Have migraines (with or without auras)
- Not currently or previously used in the past 6 months a CGRP migraine medication
- Please note, other conditions may apply.